TW200902510A - Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid - Google Patents
Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid Download PDFInfo
- Publication number
- TW200902510A TW200902510A TW97109960A TW97109960A TW200902510A TW 200902510 A TW200902510 A TW 200902510A TW 97109960 A TW97109960 A TW 97109960A TW 97109960 A TW97109960 A TW 97109960A TW 200902510 A TW200902510 A TW 200902510A
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- thiophene
- reaction
- carboxylic acid
- propoxy
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract description 5
- 238000003786 synthesis reaction Methods 0.000 title abstract description 5
- VWFVJVPPXXCWAW-UHFFFAOYSA-N 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid Chemical compound CCCOC=1SC(C(O)=O)=C(C)C=1Br VWFVJVPPXXCWAW-UHFFFAOYSA-N 0.000 title abstract description 3
- -1 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid compound Chemical class 0.000 claims abstract description 27
- 239000002904 solvent Substances 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910001868 water Inorganic materials 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052802 copper Inorganic materials 0.000 claims abstract description 9
- 239000010949 copper Substances 0.000 claims abstract description 9
- 239000003054 catalyst Substances 0.000 claims abstract description 8
- 150000002576 ketones Chemical class 0.000 claims abstract description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract description 4
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 43
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 238000005859 coupling reaction Methods 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- 238000006359 acetalization reaction Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- PDZKZMQQDCHTNF-UHFFFAOYSA-M copper(1+);thiocyanate Chemical group [Cu+].[S-]C#N PDZKZMQQDCHTNF-UHFFFAOYSA-M 0.000 claims description 5
- 238000005893 bromination reaction Methods 0.000 claims description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 claims description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 4
- 238000006192 iodination reaction Methods 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- CVOGMKGEVNGRSK-UHFFFAOYSA-N 1,2-diiodoethene Chemical group IC=CI CVOGMKGEVNGRSK-UHFFFAOYSA-N 0.000 claims description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 claims description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 239000012336 iodinating agent Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229910001923 silver oxide Inorganic materials 0.000 claims description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- 150000004703 alkoxides Chemical class 0.000 claims 2
- PQVSXGVVNMUVKK-UHFFFAOYSA-N C1=C(SC=C1S)I Chemical compound C1=C(SC=C1S)I PQVSXGVVNMUVKK-UHFFFAOYSA-N 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 229910052770 Uranium Inorganic materials 0.000 claims 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical compound C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000006146 oximation reaction Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- VSGXHZUTTFLSBC-UHFFFAOYSA-N thiophene-3-thiol Chemical compound SC=1C=CSC=1 VSGXHZUTTFLSBC-UHFFFAOYSA-N 0.000 claims 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 claims 1
- XAOJMTRGEZJSQN-UHFFFAOYSA-N 3-methyl-5-propoxythiophene-2-carboxylic acid Chemical compound CCCOC1=CC(C)=C(C(O)=O)S1 XAOJMTRGEZJSQN-UHFFFAOYSA-N 0.000 abstract description 4
- BSQKBHXYEKVKMN-UHFFFAOYSA-N 3-methylthiophene-2-carbaldehyde Chemical compound CC=1C=CSC=1C=O BSQKBHXYEKVKMN-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052783 alkali metal Inorganic materials 0.000 abstract description 4
- UTFHYWYDDMHEIL-UHFFFAOYSA-N 5-iodo-3-methylthiophene-2-carbaldehyde Chemical compound CC=1C=C(I)SC=1C=O UTFHYWYDDMHEIL-UHFFFAOYSA-N 0.000 abstract 2
- NBLCMBNKWZHYLB-UHFFFAOYSA-N 5-iodo-3-methylthiophene-2-carboxylic acid Chemical compound CC=1C=C(I)SC=1C(O)=O NBLCMBNKWZHYLB-UHFFFAOYSA-N 0.000 abstract 2
- 238000006887 Ullmann reaction Methods 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000002083 iodinating effect Effects 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LMUFKHXTMZDSLV-UHFFFAOYSA-N CCCOC1=C(C(=C(S1)C(=O)O)C2=CC3=CC=CC=C3N2)Br Chemical compound CCCOC1=C(C(=C(S1)C(=O)O)C2=CC3=CC=CC=C3N2)Br LMUFKHXTMZDSLV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000026045 iodination Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 2
- DEWLEGDTCGBNGU-UHFFFAOYSA-N 1,3-dichloropropan-2-ol Chemical compound ClCC(O)CCl DEWLEGDTCGBNGU-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- WNORZIRJJLYFFF-UHFFFAOYSA-N 2-methylcyclopropan-1-one Chemical group CC1CC1=O WNORZIRJJLYFFF-UHFFFAOYSA-N 0.000 description 1
- GZVHEAJQGPRDLQ-UHFFFAOYSA-N 6-phenyl-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C=CC=CC=2)=N1 GZVHEAJQGPRDLQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229940122598 Tryptase inhibitor Drugs 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000010953 base metal Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- IFPCETZYRXLBDJ-UHFFFAOYSA-N furan-2-carbaldehyde thiophene Chemical compound C=1C=CSC=1.O=CC1=CC=CO1 IFPCETZYRXLBDJ-UHFFFAOYSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical group [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002750 tryptase inhibitor Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
- C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
Description
200902510 九、發明說明: 【發明所屬之技術領域】 本發明涉及4-溴-3-曱基-5-丙氧基噻吩-2-羧酸的兩步 法位置選擇性烏耳曼合成。本發明也涉及可生成4-溴-3-曱基-5-丙氧基噻吩-2-羧酸的幾種中間體。 【先前技術】 W02001/13811揭示了一些化合物,包括作為類胰蛋 白酶抑制劑的[(苯曱胺)-哌啶-1-基](芳基或雜芳基)曱酮, ίο 並敘述了因類胰蛋白酶涉及各種生物過程包括使血管舒 張和支氣管鬆弛的神經肽的降解過程(Caughey, et al., J. Pharmacol. Exp. Ther., 1988, 244, pages 133-137; Franconi, et al., J. Pharmacol. Exp. Ther., 1988, 248, pages 947-951; 以及 Tam, et al., Am. J. Respir. Cell Mol. Biol., 1990, 3, 15 pages 27-32 )以及對於支氣管一組織胺反應性的調節過程 (Sekizawa, et al., J. Clin. Invest., 1989, 83, pages 175-179),從而決定的這類化合物的潛在用途。 W02005/097780更具體地揭示了式A的(苯曱胺)-哌 啶-1-基噻吩基曱酮化合物、200902510 IX. Description of the Invention: [Technical Field of the Invention] The present invention relates to a two-step position-selective Buchmann synthesis of 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid. The invention also relates to several intermediates which are capable of producing 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid. [Prior Art] W02001/13811 discloses certain compounds, including [(phenylhydrazine)-piperidin-1-yl](aryl or heteroaryl)fluorenone as a tryptase inhibitor, ίο and describes the cause Tryptase involves various biological processes including the degradation of neuropeptides that cause vasodilation and bronchial relaxation (Caughey, et al., J. Pharmacol. Exp. Ther., 1988, 244, pages 133-137; Franconi, et al. , J. Pharmacol. Exp. Ther., 1988, 248, pages 947-951; and Tam, et al., Am. J. Respir. Cell Mol. Biol., 1990, 3, 15 pages 27-32) and The regulation of bronchial-histamine reactivity (Sekizawa, et al., J. Clin. Invest., 1989, 83, pages 175-179), thereby determining the potential use of such compounds. W02005/097780 discloses more specifically the (benzoguanamine)-piperidin-1-ylthienyl fluorenone compound of formula A,
20 200902510 其製備,及其在治療可通過抑制類胰蛋白酶而治療的疾病 方面的用途。W02005/097780還揭示,式A的化合物是 通過下述化合物16與化合物10的偶合反應,以及偶合產 物隨後的脫保護反應而製備的。 化合物16是按照下述多步驟製備法所製備 KOH cs« Λ〇, ο20 200902510 Its preparation, and its use in the treatment of diseases which can be treated by inhibition of tryptase. W02005/097780 also discloses that the compound of formula A is prepared by the coupling reaction of compound 16 with compound 10 below, and the subsequent deprotection of the coupling product. Compound 16 was prepared according to the following multi-step preparation method KOH cs « Λ〇, ο
NaH 41% 11NaH 41% 11
I η N 6 J—O MeONa 人人^ ° r.. 0^~B 13 77%I η N 6 J-O MeONa Everyone ^ ° r.. 0^~B 13 77%
Ο Ο 14 100%Ο Ο 14 100%
Ct^CH MeO,Ct^CH MeO,
ΟΟ
UOH β1% 15 16 雖然上述程序能製備中間體16,但其採用了繁多的步 驟,採用了氣味特徵令人不快的無環中間體,而且不是從 易得的噻吩基原料開始製備。 【發明内容】 本發明涉及式16的4-溴-3-曱基-5-丙氧基噻吩-2-羧酸 化合物的特定位置合成,包括以下步驟: 在一種醇溶劑中使3-曱基噻吩-2-曱醛發生縮醛化; 10 200902510 甲其^、種非'子極性溶劑或烴溶射,破化該縮搭化3_ ^甲路以生成對應的峨化和縮搭化3-甲基噻 吩-2-甲醒·產物; 用水處卿魏和祕化絲,以生成對應的5_蛾-3_ 甲基噻吩-2-甲醛; 在酮溶劑中,將5射甲基嗟吩_2_甲酸氧化為對應 的5-峨-3-ψ基喧吩_2_叛酸; 10 15 使用種銅惟化劑在丙醇中使5_峨_3_甲基噻吩_2_竣 酸與驗金屬丙醇鹽發生烏耳曼偶合,以生《3_曱基·5_丙 氧基嗟吩-2-缓酸; 醋化3-甲基_5_丙氧基。塞吩,以生成㈣㈣ 基3-甲基-5-丙氧基噻吩_2_羧酸酯; 漠化3_甲基_5_丙氧基嘆吩_2_㈣’以生成對應的烧 基4 >臭-3-甲基-5-丙氧基σ塞吩_2_致酸g旨;以及 用鹼使烷基4-溴-3-曱基-5-丙氧基噻吩_2_羧酸酯發生 鹼性水解,以生成4-溴-3-甲基-5-丙氧基噻吩_2_羧酸。 本發明進一步涉及下列化合物 〇UOH β1% 15 16 Although the above procedure enables the preparation of intermediate 16, it employs a wide variety of procedures, using an acyclic intermediate having an unpleasant odor characteristic, and is not prepared starting from a readily available thiophene-based starting material. SUMMARY OF THE INVENTION The present invention is directed to a specific positional synthesis of a 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid compound of formula 16, comprising the steps of: 3-mercaptoyl in an alcohol solvent Thiophene-2-furaldehyde is acetalized; 10 200902510 A non-sub-polar solvent or a hydrocarbon spray, which breaks down the 3_^ pathway to form the corresponding deuterated and condensed 3-a The thiophene-2-methyl waking product; the water is used in the Wei and the secreted silk to form the corresponding 5_Moth-3_methylthiophene-2-carbaldehyde; in the ketone solvent, the 5-methyl thiophene-2- Oxidation of formic acid to the corresponding 5-indole-3-indenyl porphin-2_ tacrotic acid; 10 15 using a copper-based scavenger to make 5_峨_3_methylthiophene-2-indole in propanol The metal propanolate is subjected to a Neumann coupling to produce "3_mercapto-5-propoxyphene-2-hypoacid; acetate 3-methyl-5-propoxy. Cephene to form (tetra)(tetra)yl 3-methyl-5-propoxythiophene-2-carboxylate; desertification 3_methyl_5-propoxysin_2_(tetra)' to generate the corresponding alkyl group 4 > Odor-3-methyl-5-propoxy σ-septene-2_acid-acid; and base 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid The ester undergoes alkaline hydrolysis to form 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid. The invention further relates to the following compounds 〇
/°/°
0 以及0 and
彼等中間體係通過應用上述過程用以製備4_漠_3_甲基 兩氧基噻吩-2-羧酸。 20 200902510 本發明之詳述 通過參閱以下詳細說明將能更好地理解本發明。 定義 5 如上文所用以及貫穿本發明之全部說明,包括所附的 申請專利範圍,下列縮寫和術語應被理解為具有以下含 義,除非另行說明: 「縮醛化」意為在非水溶液酸性條件下例如使用乾 HC1或四丁基三溴化物,與一種醇如MeOH、EtOH或1,2-10 乙二醇,或與一種醇源如原曱酸三甲酯進行反應。 「醇溶劑」意為MeOH、EtOH或1,2-乙二醇等。 「驗金屬」意為链、鈉、鉀或鉋。 「鹼金屬丙醇鹽」意為用一種強鹼處理丙醇而得到的 一種鹽。強驗的例子有Cs2C03、驗金屬的驗如NaH、 15 NaHMDS、KHMDS、LiHMDS、二異丙醯胺經(LDA), 或烧基金屬如烧基链、烧基钟、烧基納以及烧基鎮’其中 的烷基是Cw烷基,更為首選的是丁基,例如、CsOPr、 NaOPr、LiOPr 或 KOPr。 「溴化有機溶劑」意為一種可用於實現溴化反應的極 20 性或惰性有機溶劑,例如乙腈、有機酸如乙酸或丙酸,或 鹵代溶劑如二氯曱烧或氯仿。 「溴化」意為與Br2或適當的溴源如NBS反應。 「銅催化劑」意為一種能實現烏耳曼偶合反應的銅催 化劑,選自 CuSCN、CuBr、Cul、CuCn、CuBF4、CuPF6、 200902510These intermediate systems were prepared by applying the above procedure for the preparation of 4_methyl-3-methyldioxythiophene-2-carboxylic acid. 20 200902510 DETAILED DESCRIPTION OF THE INVENTION The present invention will be better understood by reference to the following detailed description. Definitions 5 As used above and throughout the description of the invention, including the scope of the appended claims, the following abbreviations and terms are understood to have the following meanings unless otherwise indicated: "acetalization" means under acidic conditions of non-aqueous solutions For example, dry HCl or tetrabutyltribromide is used, and is reacted with an alcohol such as MeOH, EtOH or 1,2-10 ethylene glycol, or with an alcohol source such as trimethyl orthoformate. The "alcohol solvent" means MeOH, EtOH or 1,2-ethanediol or the like. "Metal" means chain, sodium, potassium or planer. "Alkali metal propoxide" means a salt obtained by treating propanol with a strong base. Examples of strong tests are Cs2C03, metal tests such as NaH, 15 NaHMDS, KHMDS, LiHMDS, diisopropylamine (LDA), or a base metal such as a burnt-chain, a ruthenium, a ruthenium, and a base. The alkyl group of the town is Cw alkyl, more preferably butyl, for example, CsOPr, NaOPr, LiOPr or KOPr. The "brominated organic solvent" means a polar or inert organic solvent which can be used for the bromination reaction, such as acetonitrile, an organic acid such as acetic acid or propionic acid, or a halogenated solvent such as dichlorohydrin or chloroform. "Bromide" means reacting with Br2 or a suitable source of bromine such as NBS. "Copper catalyst" means a copper catalyst capable of achieving a Neumann coupling reaction selected from the group consisting of CuSCN, CuBr, Cul, CuCn, CuBF4, CuPF6, 200902510
CuOTf、CuPF6、CuBr2、CuCl2、以及 。 「偶合助溶劑」意為能與内醇偶合溶劑聯合使用的另 -種惰性有機溶劑,例如THF、甲苯、2_甲基thf,或二 曱氧基乙烧。 ^旨化」意綠基在I旨化條件下向它對應的醋轉化, ==與一種醇在一種酸存在的條件下反應,或通過用 基化劑如Me2S〇4、笨甲基漠和_處理,使酸發 生烷基化而轉化為其對應的羧酸陰離子。 種溶劑」意為—種惰性極性有機溶劑,例如一 乙基轉以及二㈣。 基曱麵(ΤΒΜΕ)、異丙基 「驗性水解」意為使用舲 15 20 或鉀的氫氧化物祕土金屬;^的氫氧化物例f鈉 「爾·!」意為化物以實, 當的魏劑如細進行反在條件下與12、IC1或適 己烷基鋰、第二丁其# …,強鹼的例子為烷基鋰鹼如環 「诚化->卞丨1 、正丁基鋰以及二異丙基醯胺鋰等。 硬化洛劑」意為—葙 _ 中非質子純溶毅貞子極性㈣錢溶劑,其 基乙基喊、THF、丨,4_二τ基甲躺(TBME)、異丙 是曱苯、二甲苯或庚料#或1>3-二氧戊Μ ’烴溶劑 「Γ溶劑」立意為-種C3-5酮如丙酮。CuOTf, CuPF6, CuBr2, CuCl2, and . "Coupling cosolvent" means another inert organic solvent which can be used in combination with an internal alcohol coupling solvent, such as THF, toluene, 2-methylthene, or dimethoxyethane. The meaning of the green base is converted to its corresponding vinegar under the conditions of I, == reacting with an alcohol in the presence of an acid, or by using a baseing agent such as Me2S〇4, stupid methyl desert Treatment, the alkylation of the acid to its corresponding carboxylic acid anion. "Solvent" means an inert polar organic solvent such as ethyltrans and di(tetra).曱 曱 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验 验When the Wei agent is finely reacted under the conditions of 12, IC1 or hexane-based lithium, the second butyl group ..., an example of a strong base is an alkyl lithium base such as a ring "Shenghua-> 卞丨1, n-Butyllithium and lithium diisopropylamide, etc. Hardening agent means - 葙 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ A lie (TBME), isopropyl is benzene, xylene or heptane # or 1> 3-dioxol quinone 'hydrocarbon solvent "Γ solvent" is intended to be a C3-5 ketone such as acetone.
NaCIO乳H思為用灿1〇2/ NaH2P〇4.H2〇/氨基石黃酸、 2 P ’’’、1〜10的添加劑、ΚΜη04、氧化銀、H2〇2或 -10· 200902510 臭氧進行處理。 【實施方式】 在依照本發明之方法的一具體實施例中,溴化有機溶 5 劑是乙酸。 在依照本發明之方法的一具體實施例中,縮醛化是於 約-10°C至約20°C的溫度條件下進行。 在依照本發明之方法的一個具體實施例中,碘化是在 THF中進行。 ίο 在依照本發明之方法的一具體實施例中,碘化所用的 強鹼是正丁基鋰。 在依照本發明之方法的一具體實施例中,碘化劑是 12、二碘乙烯、1C卜或NIS。 在依照本發明之方法的一具體實施例中,碘化是於 15 約-80°C至約0°C的溫度條件下進行。 在依照本發明之方法的一具體實施例中,氧化反應是 ' 以NaC102/NaH2P04.H20/氨基磺酸進行。 在依照本發明之方法的一具體實施例中,酮溶劑是丙 酉同0 20 在依照本發明之方法的一具體實施例中,氧化是於 約-10°C至約30°C的溫度條件下進行。 在依照本發明之方法的另一具體實施例中,鹼金屬丙 醇鹽是 CsOPr、NaOPr、LiOPr 以及 KOPr。 在依照本發明之方法的另一具體實施例中,銅催化劑 -11 - 200902510 是 CuOTf、CuSCN、CuBr 或 CuI。 在依照本發明之方法的另一具體實施例中,取決於所 用的溶劑和壓力,偶合反應是於約70 °C至約120 °C的加 熱條件下進行。 5 在依照本發明之方法的另一具體實施例中,溴化是於 約0°C至約100°C的溫度條件下進行,更為首選的是 750C。 在依照本發明之方法的另一具體實施例中,溴化是以 Br2進行。 10 在依照本發明之方法的另一具體實施例中,鹼金屬丙 醇鹽是丙醇鈉。 在依照本發明之方法的另一具體實施例中,銅催化劑 是 CuSCN、CuBr 或 Cul。 在依照本發明之方法的另一具體實施例中,水解是於 15 約0°C至約50°C的溫度條件下進行。 在依照本發明之方法的另一具體實施例中,偶合反應 ' 是以一種偶合助溶劑例如THF、曱苯、2-曱基THF或二 曱氧基乙烷進行。 20 實例 製備細節 原料可以購入或通過應用或改進已知的方法來製 備,或利用其顯然的化學等效物。 通過參考以下典型的本發明非限制性實例,本發明可 -12- 200902510 更好地得到理解。提供以下實例是為了更充分地說明本發 明的具體實施例。然而,彼等無論如何不應被理解為是限 制本發明的寬廣範圍。 在下文列出的核磁共振光譜(NMR)中,化學位移以 5 ppm表示,以四甲基石夕烧為内標。諸縮寫具有下列含義: br=寬**%,dd=雙峰,s =單峰;m=多重峰。 以下實例中所述的4-溴-3-曱基-5-丙氧基噻吩-2-羧酸 的合成可以如下示意圖I表示。NaCIO Milk H is made with Can 1〇2/ NaH2P〇4.H2〇/Amino-Rhein, 2 P ''', 1~10 Additive, ΚΜη04, Silver Oxide, H2〇2 or -10· 200902510 Ozone deal with. [Embodiment] In a specific embodiment of the method according to the present invention, the brominated organic solvent is acetic acid. In a specific embodiment of the method according to the invention, the acetalization is carried out at a temperature of from about -10 ° C to about 20 ° C. In a particular embodiment of the method according to the invention, the iodination is carried out in THF. Ίο In a specific embodiment of the method according to the invention, the strong base used for iodination is n-butyllithium. In a specific embodiment of the method according to the invention, the iodinating agent is 12, diiodoethylene, 1C or NIS. In a specific embodiment of the method according to the invention, the iodination is carried out at a temperature of from about 15 ° C to about 0 ° C. In a particular embodiment of the process according to the invention, the oxidation reaction is carried out as 'NaC102/NaH2P04.H20/sulfamic acid. In a specific embodiment of the method according to the invention, the ketone solvent is propylene ketone. In a specific embodiment of the method according to the invention, the oxidation is at a temperature of from about -10 ° C to about 30 ° C. Go on. In another embodiment of the method according to the invention, the alkali metal propoxides are CsOPr, NaOPr, LiOPr and KOPr. In another embodiment of the method according to the invention, the copper catalyst -11 - 200902510 is CuOTf, CuSCN, CuBr or CuI. In another embodiment of the process according to the invention, the coupling reaction is carried out under heating conditions of from about 70 ° C to about 120 ° C, depending on the solvent and pressure employed. 5 In another embodiment of the method according to the invention, the bromination is carried out at a temperature of from about 0 ° C to about 100 ° C, more preferably 750 ° C. In another embodiment of the method according to the invention, the bromination is carried out as Br2. In another embodiment of the method according to the invention, the alkali metal propoxide is sodium propoxide. In another embodiment of the method according to the invention, the copper catalyst is CuSCN, CuBr or Cul. In another embodiment of the method according to the invention, the hydrolysis is carried out at a temperature of from about 0 ° C to about 50 ° C. In another embodiment of the process according to the invention, the coupling reaction is carried out as a coupling cosolvent such as THF, toluene, 2-mercapto THF or dimethoxyethane. 20 EXAMPLES Preparation Details The starting materials can be purchased or prepared by applying or modifying known methods, or utilizing their apparent chemical equivalents. The invention is better understood by reference to the following non-limiting examples of typical inventions of the invention. The following examples are provided to more fully illustrate the specific embodiments of the invention. However, they should not be construed as limiting the broad scope of the invention in any way. In the nuclear magnetic resonance spectroscopy (NMR) listed below, the chemical shift is represented by 5 ppm, and the tetramethyl zephyr is used as an internal standard. The abbreviations have the following meanings: br = width ** %, dd = doublet, s = singlet; m = multiplet. The synthesis of 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid described in the following examples can be represented by the following scheme I.
ίο 示意圖IΊο Schematic I
HO •13- 200902510 實例1 : 5-峨-3-曱基β塞吩-2-甲搭 向原甲酸三甲醋(367 g,3.45莫耳)和四丁基三演化 物(11.0 g,0.0224莫耳)的甲醇(2 〇 L)溶液中,於2 與1〇〇C之間的溫度下在一段50分鐘的時間内加入”基 5 噻吩-2-甲醛(400 g,2.85莫耳)。於1.5小時之後,判^ (GCMS)縮醛化已完成。將反應混合物在旋轉蒸發器上 濃縮,即得550 g粗製噻吩縮醛,為一種深黃色油。將該 縮搭溶於THF(5.0L)’冷卻至_6〇 〇c並在一 ίο 耳)。於_60 °C將該混合物攪拌45分鐘。在一段4〇分鐘 的時間内,於-60 °C向此溶液加入碘的THF溶液(871 g, 1.5 L THF,3.42莫耳)。於5分鐘之後,判斷(Ηριχ)碘 化已元成。於-60 °C用曱醇(0.350 L)終止反應後,將該 反應混合物加熱至15 %並保持過夜。將該深黃色反應混 15 合物在旋轉蒸發器上濃縮,即得一種深黃色油。加水(9 L·) 之後,用二氯甲烷(1 X 8 L,1 x 2 L)萃取該混合物。將 合併後一氯甲烧溶液在旋轉蒸發器上濃縮,即得8〇8 g 5_ 碘-3-曱基噻吩-2-曱醛,為一種深黃色固體。將此粗製5_ 織-3-甲基α塞吩-2-曱醒·直接用於下一步驟。 20 H (CDC13) δ 2.5 (s,3Η),7.2 (s,1Η),9.9 (s, 1Η)。LCMS (ESI) m/z 296.87 (Μ-Η)。 實例2 : 5_破基噻吩_2_羧酸 於2 °C在一段3分鐘時間内向5_碘_3_甲基噻吩_2_甲 -14- 200902510 醛(650 g,2.58莫耳)、丙酮(2.6 L)和水(1.5 L)的混 合物中,加入氨基磺酸(277 g,2.84莫耳)和NaH2P04.H2〇 ( 533 g,3·86莫耳)。於8°C在一段3小時時間内向此懸 浮液加入NaC102溶液(306 g,在1.3 L水中,2.71莫耳)。 添加期間未觀察到黃色氣體。5分鐘後,(HPLC)判斷反 應已完全。於18 DC加水(7.3 L)之後,過濾該懸浮液, 並用4 X 800 mL水、1 X 800 mL丙酮/正庚烷(1 : 5),以 及1 x 200 mL正庚烷依次洗滌反應器和濾餅。乾燥產物即 得539 g (89%) 5-碘-3-曱基噻吩-2-羧酸為固體。 1h NMR (DMSO-d6) δ 2.4 (s,3H),7.3 (s , 1Π),13.1 (s,1Η)。 實例3 : 4-溴-3-曱基-5-丙氧基噻吩-2-羧酸 將 1-丙烷(3.85 L)、Cs2C03 ( 1.73 kg,5.31 莫耳) 和(CU〇Tf>2·曱苯(35·2 g,〇 〇68莫耳)的混合物加熱至 90 °C,在一段7分鐘的時間内加入5-碘-3-曱基噻吩-2-羧 酸(500 g ’ 1.87莫耳)。將生成的懸浮液於95 〇c攪拌18 小時’以HPLC判定烏耳曼偶合反應已完成。將該反應混 合物冷部至40 〇C ’並加入二氯曱烧(1 9 L)。於40 ± 1 °C 在^又1 ·5小時的時間内向此懸浮液加入Me2S04 ( 350 mL,3·60莫耳)。於40。(:再攪拌1小時,將該懸浮液冷 卻至至溫。加入二氣甲烷(19 L)並用矽藻土過濾該懸浮 液。用5 x 700 mL·二氣曱烷洗滌反應器和濾餅。將合併後 濾液在旋轉蒸發器上濃縮,即得505 g3-曱基-5-丙氧基噻 -15- 200902510 吩-2-羧酸甲酯’為一種深黃色油。將此物質溶於二氯甲烧 (4.2L) /正庚烷(4.7L),然後於3〇c在—段分鐘的 時間内加入演(95 mL’ 1.88莫耳)。再過3〇分鐘後,將 該反應混合物以旋轉蒸發濃縮,即得587 g深黃色固體。 5 加入1,4 一今烧(5.5 L)和水(4.6 L),在於3 °C加入 LiOH ( 223 g,9.33莫耳)。將該反應混合物於室溫攪拌 20小時。用HC1 (1.4L,6N)於2°C終止反應,加入水 (1.1 L )。然後,過濾該懸浮液,用11 〇〇 mL二Β号烧/水(2 : 3 )、3 X 600 mL正庚烷和11〇〇 mL丙酮/正庚烷(j : 5 ) ίο 洗滌反應器和濾餅。乾燥該固體,即得318 g粗製4-溴-3- 曱基-5-丙氧基噻吩-2-羧酸。通過在乙腈(15 L) /水(18 L)中重結晶而進一步純化該粗製產物並加以乾燥,即得 248 g (以3-甲基噻吩-2-甲醛計,產率為46%)所需的4-溴-3-曱基-5-丙氧基嗟吩-2-敌酸,為一種淡黃色固體。 15 HPLC :約 98 °/〇純度。C9HuBr03S 分析計算值:c,38.72 ; Η ’ 3.97。實際值:C,38.98 ; Η,3.77。MS (ESI+) m/z 279 [Μ] ° 1H-NMR(dmso-d6) δ 13.0 (s » 1 Η)» 4.2 (t > 2Η)' 2.4 (s » 3H),1.8 (m,2H),1.0(t’3H)。13C-NMR(dmso-d6)3 163, 20 162 , 143 , 113 , 96 , 77 , 22 , 16 , 11 。 •16-HO •13- 200902510 Example 1: 5-indole-3-indolyl β-sentene-2-methylate to trimethylacetate orthoformate (367 g, 3.45 mol) and tetrabutyl tri-evolution (11.0 g, 0.024 mol) In a solution of methanol (2 〇L), add "5 thiophene-2-carbaldehyde (400 g, 2.85 mol) at a temperature between 2 and 1 〇〇C over a period of 50 minutes. After an hour, the acetalization of (GCMS) was completed. The reaction mixture was concentrated on a rotary evaporator to give 550 g of crude thiophene acetal as a dark yellow oil. 'Cool to _6〇〇c and in a ίο ear.) Stir the mixture at _60 °C for 45 minutes. Add iodine in THF at -60 °C over a period of 4 Torr. 871 g, 1.5 L THF, 3.42 mol. After 5 minutes, judge (Ηριχ) iodization has been completed. After quenching with decyl alcohol (0.350 L) at -60 °C, the reaction mixture is heated to 15 % and kept overnight. The dark yellow reaction mixture was concentrated on a rotary evaporator to give a dark yellow oil. After adding water (9 L·), dichloromethane (1×8) L, 1 x 2 L) extracting the mixture. The combined chloroformic solution was concentrated on a rotary evaporator to obtain 8 〇 8 g of 5 iodo-3-mercaptothiophene-2-furaldehyde as a dark yellow Solid. The crude 5-methyl-3-methyl-e-phen-2-pyrene was used directly in the next step. 20 H (CDC13) δ 2.5 (s, 3 Η), 7.2 (s, 1 Η), 9.9 ( s, 1Η). LCMS (ESI) m/z 296.87 (Μ-Η). Example 2: 5_ thiophene-2-carboxylic acid at 5 ° C for a period of 3 minutes to 5-iodo-3-methyl Thiophene-2-methyl-14- 200902510 A mixture of aldehyde (650 g, 2.58 mol), acetone (2.6 L) and water (1.5 L), adding sulfamic acid (277 g, 2.84 mol) and NaH2P04.H2 〇 (533 g, 3.86 mol). To this suspension was added a solution of NaC 102 (306 g in 1.3 L of water, 2.71 mol) over a period of 3 hours at 8 ° C. No yellow gas was observed during the addition. After 5 minutes, the reaction was judged to be complete (HPLC). After adding water (7.3 L) to 18 DC, the suspension was filtered, and 4 X 800 mL water, 1 X 800 mL acetone/n-heptane (1:5), and Wash the reactor and filter cake sequentially with 1 x 200 mL of n-heptane. Dry product To give 539 g (89%) 5- iodo-3-yl thiophene-2-carboxylic acid Yue as a solid. 1h NMR (DMSO-d6) δ 2.4 (s, 3H), 7.3 (s, 1 Π), 13.1 (s, 1 Η). Example 3: 4-Bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid 1-propane (3.85 L), Cs2C03 (1.73 kg, 5.31 mol) and (CU〇Tf>2·曱A mixture of benzene (35. 2 g, 〇〇68 mol) was heated to 90 ° C and 5-iodo-3-indolylthiophene-2-carboxylic acid (500 g ' 1.87 mol) was added over a period of 7 minutes. The resulting suspension was stirred at 95 ° C for 18 hours to determine the completion of the Neumann coupling reaction by HPLC. The reaction mixture was cooled to 40 ° C ' and added to dichloromethane (1 9 L). 40 ± 1 °C Me2S04 (350 mL, 3.60 moles) was added to the suspension over a period of 1.5 hours. At 40. (: stirring for an additional 1 hour, the suspension was cooled to warm. Add two gas methane (19 L) and filter the suspension with diatomaceous earth. Wash the reactor and filter cake with 5 x 700 mL dioxane. Concentrate the filtrate on a rotary evaporator to obtain 505 g3- Mercapto-5-propoxythia-15- 200902510 Methyl phen-2-carboxylate is a dark yellow oil. This material is dissolved in dichloromethane (4.2 L) / n-heptane (4.7 L). Then join in 3〇c in a minute 95 mL ' 1.88 moles. After a further 3 minutes, the reaction mixture was concentrated by rotary evaporation to give 587 g of dark yellow solid. 5 </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> </ RTI> LiOH (223 g, 9.33 moles) was added at 3 ° C. The reaction mixture was stirred at room temperature for 20 hours. The reaction was quenched with HCl (1.4L, 6 N) at 2 ° C and water (1.1 L) was then added. , the suspension was filtered, and the reactor was washed with 11 〇〇 mL of hydrazine/water (2:3), 3×600 mL of n-heptane and 11 〇〇mL of acetone/n-heptane (j: 5 ) ίο The cake was dried and 318 g of crude 4-bromo-3-indolyl-5-propoxythiophene-2-carboxylic acid were obtained by recrystallization from acetonitrile (15 L) / water (18 L). The crude product was further purified and dried to give the desired 4-bromo-3-indolyl-5-propoxyindole as 248 g (yield: 46% of 3-methylthiophene-2-carbaldehyde). Phen-2-carboxylic acid, a pale yellow solid. 15 HPLC: about 98 ° / 〇 purity. C9 HuBr03S analytical value: c, 38.72; Η ' 3.97. Actual value: C, 38.98; Η, 3.77. MS (ESI+ m/z 279 [Μ] ° 1H-NMR(dmso-d6) δ 13.0 (s » 1 Η)» 4.2 (t > 2Η)' 2.4 (s » 3H), 1.8 (m, 2H), 1.0 (t'3H). 13C-NMR (dmso-d6) 3 163, 20 162 , 143 , 113 , 96 , 77 , 22 , 16 , 11 . •16-
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89610907P | 2007-03-21 | 2007-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200902510A true TW200902510A (en) | 2009-01-16 |
Family
ID=39639204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW97109960A TW200902510A (en) | 2007-03-21 | 2008-03-21 | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR065793A1 (en) |
| TW (1) | TW200902510A (en) |
| WO (1) | WO2008115912A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016532721A (en) | 2013-10-07 | 2016-10-20 | バイエル ファーマ アクチエンゲゼルシャフト | Cyclic thienouracil carboxamide and uses thereof |
| CN105085469B (en) * | 2015-09-11 | 2017-07-11 | 沧州那瑞化学科技有限公司 | A kind of preparation method of the carboxylic acid of 5 chlorothiophene 2 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2005000039A (en) * | 2004-03-26 | 2005-10-31 | Aventis Pharma Inc | HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE |
-
2008
- 2008-03-18 WO PCT/US2008/057336 patent/WO2008115912A1/en not_active Ceased
- 2008-03-19 AR ARP080101141 patent/AR065793A1/en unknown
- 2008-03-21 TW TW97109960A patent/TW200902510A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR065793A1 (en) | 2009-07-01 |
| WO2008115912A1 (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2004099149A1 (en) | Process for producing 2-chloro-5-fluoro-3-substituted pyridine or a salt thereof | |
| JP2011046751A (en) | Synthesis of himbacine analog | |
| JP2018008985A (en) | Process for preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-1yl)-acetic acid esters | |
| TW200902510A (en) | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid | |
| TWI343909B (en) | Process for making galantamine | |
| CN102245591B (en) | Process for manufacturing 5-formyl-pyridine-2,3-dicarboxylic acid esters | |
| JP2012524044A (en) | Process for the preparation of 2,4,6-octatrien-1-acid and 2,4,6-octatrien-1-ol | |
| EP3119741B1 (en) | An improved process for the synthesis of dimethyl fumarate | |
| US20100185008A1 (en) | Method for Producing Fenofibrate | |
| KR20090055638A (en) | Method for preparing 2,5-bis- (2,2,2-trifluoroethoxy) -N- (2-piperidylmethyl) benzamide and its salts | |
| TW200844100A (en) | Regio-selective Ullmann synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid | |
| CN101263105B (en) | Process for preparing β-keto ester compounds | |
| JP3911732B2 (en) | Process for producing dialkyl 5-bromo-isophthalate | |
| CN110627683A (en) | A kind of preparation method of indanone intermediate | |
| JP2013139427A (en) | Method of improving and synthesizing isoquinolin-4(3h)-ones | |
| JP4182396B2 (en) | Method for producing aromatic aldehyde | |
| JP4896476B2 (en) | Methyloxymethylaminopyridine derivative and method for producing the same | |
| JP3013022B2 (en) | Method for producing alkyl 3-phthalidylideneacetate | |
| KR100515922B1 (en) | Process for preparing of dibenzothiepin | |
| JP4050915B2 (en) | 2-Adamantanone production method | |
| KR100343641B1 (en) | Process for preparing ethyl 3-(2,5,6- trihalopyridin-3-yl)-3-oxopropionate from 2,5,6-trihalo-3-cyanopyridine | |
| CN119019241A (en) | Synthesis method of α-cyclopentylmandelic acid | |
| FR2918662A1 (en) | Preparation of fenofibrate from fenofibric acid comprises preparing fenofibric acid chloride by action of chlorinating agent on the fenofibric acid, in situ, then reacting isopropanol without isolation of acid chloride | |
| JPH04134055A (en) | Dialkylaminoacrylic acid allyl ester and production thereof | |
| JPH0841070A (en) | Production of pyridonecarboxylic acid derivative |